Bristol-Myers Squibb Co
The ‘Trump trade’ is on pause. Political uncertainty is now in the driver’s seat
It didn’t take long to remember what a second Donald Trump presidential term would mean for the stock market, did it? Unpredictability. Random attacks. No one safe. Mercurial positions. The only difference? Former Vice President Mike Pence meant nothing. He was supposed to mean nothing. Now the Republican candidate’s new running mate, Sen. JD Vance […]
Read More
Pfizer struggles to claw back faith with Wall Street and its employees as it recovers from the Covid decline
Kena Betancur | Corbis News | Getty Images Pfizer had a “phenomenal” first quarter — and Wall Street took notice, CEO Albert Bourla told thousands of employees during a companywide town hall on May 2, according to a recording heard by CNBC. A day earlier, the pharmaceutical giant’s stock had closed 6% higher after its […]
Read More
Healthy Returns: Drugmakers release promising cancer drug data – and AstraZeneca wins big
Attendees walk through the lobby at the American Society of Clinical Oncology annual meeting in Chicago. Tim Boyle | Bloomberg | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! I’m back in New York City after spending the last weekend in […]
Read More
This up-and-coming cancer treatment could be a $25 billion market opportunity — it’s already a hotbed for M&A
Skynesher | E+ | Getty Images Big pharma is betting billions on an up-and-coming class of cancer treatments that some on Wall Street are calling a “massive opportunity.” It’s called targeted radiopharmaceutical therapy. It essentially delivers radiation directly into tumors by attaching a radioactive particle to a targeting molecule. RBC Capital Markets sees a $25 […]
Read More
A corner of the cancer therapy market is heating up—Here are the names investors need to know
There’s been a lot of attention lately on a corner of the oncology market called radiopharmaceuticals. The therapy seeks to destroy cancer cells by binding a radioactive particle to a targeted molecule and then dispatching it directly into the tumor. There are currently two products on the market from Novartis and a slew of clinical […]
Read More
Judge rejects J&J, Bristol Myers Squibb challenges to Medicare drug-price negotiations
Jonathan Raa | Nurphoto | Getty Images A federal judge in New Jersey on Monday rejected Johnson & Johnson‘s and Bristol Myers Squibb‘s legal challenges to the Biden administration’s Medicare drug-price negotiations, ruling that the program is constitutional. The decision is another win for the White House in a bitter legal fight with several drugmakers […]
Read More
Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss
The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, on Dec. 27, 2023. Adam Glanzman | Bloomberg | Getty Images Bristol Myers Squibb on Thursday reported first-quarter revenue that topped expectations as its blockbuster blood thinner Eliquis and several new drugs posted sales growth. But the pharmaceutical company swung to […]
Read More
These are the top rated 5 companies to get the job done for in India, in accordance to LinkedIn
These are the 2024 best businesses in India, according to LinkedIn. Deepak Sethi | E+ | Getty Photos LinkedIn has unveiled its eighth yearly list of best corporations to work for in India, and corporations that prioritized its employees’ working experience and expansion dominated this year’s ranking. From mass layoffs to the adoption of generative […]
Read More
Biotech stocks are ready to break out. They just need one more thing
While debate rages on about when the Federal Reserve might start cutting interest rates, biotech industry analysts are making the case that the argument for stocks in the sector is growing. The central bank has held rates steady since last July as it patiently waits for more signs that inflation is cooling. But a reading […]
Read More
Healthy Returns: J&J cell therapy gains new edge over Bristol Myers rival
Jonathan Raa | Nurphoto | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Hi folks! Two competing cell therapies from Bristol Myers Squibb and Johnson & Johnson both got good news from the Food and Drug Administration on Friday. But J&J’s drug is […]
Read More